We Work for Health Virginia

08/03/2026

Innovation, not isolation, is how America stays ahead in biotech. As billions of dollars in drug patents expire, the U.S. should focus on attracting top talent, investing in research, and helping American companies develop the next generation of lifesaving treatments.

The goal should be to outcompete China through innovation, not slow medical breakthroughs with policies that make it harder for patients to access tomorrow's cures. Read more here:

If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race.

07/07/2026

Most-Favored-Nation (MFN) pricing may promise lower drug prices, but tying U.S. prices to those set by foreign governments risks importing their price-control systems.

Rather than adopting policies that could discourage investment in new medicines, the U.S. should address unfair foreign pricing practices while protecting American pharmaceutical innovation and the development of future lifesaving treatments.

Read more here:

Executive Summary U.S. patients pay more than patients in other wealthy countries for the same branded prescription drugs, but that gap does not prove that . . .

05/28/2026

Congress is right to take a closer look at the 340B program and the hidden costs it creates for patients, families, employers, and taxpayers.

Thank you to Congressman Morgan Griffith for leading oversight efforts and pushing for commonsense 340B reforms that put patients first, lower healthcare costs, and protect access to affordable, community-based care for Virginians.

Read the Op-Ed here:

What was meant to be a patient-focused program is now a hospital markup program where large, tax-exempt hospital systems buy discounted drugs, mark them up by as much as 1,000% or more and bill pat…

05/21/2026

Thank you, Governor Abigail Spanberger for vetoing the Prescription Drug Affordability Board legislation (HB 483/SB 271) and standing up for patients, innovation, and access to life-saving treatments in Virginia.

This legislation would have created uncertainty for healthcare stakeholders and risked limiting access to new medicines for Virginians who need them most.

We appreciate Governor Spanberger’s leadership and commitment to policies that protect patient access and support continued medical innovation.

05/07/2026

Latino communities face disproportionate health challenges and Washington’s latest healthcare proposals risk making that worse — increasing delays, restricting access to treatments, and limiting future innovation. Real reform should lower costs by increasing transparency, holding insurers and PBMs accountable, and putting patients first. Find out more here:

The latest push in Washington to lower healthcare costs is overlooking the needs of those with the most at stake: Latino patients.Latino communities carry some of the highest rates of c

04/30/2026

We’re grateful to Senator Mark Warner for co-sponsoring the PBM Price Transparency and Accountability Act (S.3345), a meaningful step toward lowering costs and improving transparency for patients.

Pharmacy benefit managers play a major role in determining what patients pay and what treatments they can access. Bringing more accountability to that process helps ensure the system works as intended.

Read more here:

PBM reform championed by Sen. Warner is a necessary step to lower health care costs for patients, VA Bio’s John Newby writes in a guest column

04/21/2026

VAHO applauds Governor Abigail Spanberger's amendments to SB 271/HB 483, taking an important step to protect cancer patients’ access to care.

By requiring further study and a 2027 vote before certain drug pricing provisions take effect, these changes ensure policies won’t unintentionally disrupt treatment in communities across the Commonwealth.

Cancer patients need solutions that lower costs without risking access. VAHO urges the General Assembly to support these patient-focused amendments.

04/14/2026

Thank you, Governor Abigail Spanberger for taking a smart and measured approach to the PDAP legislation, SB271/ HB 483, which would have established a Prescription Drug Affordability Panel.

By requiring the Maximum Fair Price provisions to be re-enacted in 2027, this amendment stops a flawed policy from taking effect now and sends a clear signal that Virginia should not rush into government price-setting schemes that could undermine patient access and medical innovation.

This is a major win for patients, for innovation, and for a stronger life sciences future in the Commonwealth.

04/12/2026

Here's another perspective on how America can thrive in this competitive global economy.

A burdensome regulatory environment is pushing clinical trials overseas.

04/10/2026

Interesting article about our growing dependence on China and what we need to do about it.

The United States is increasingly reliant on China for pharmaceuticals, with the potential for the Chinese Communist Party to gain control of the global supply chain, posing a national security ris…